$125M Series A: Ambros Therapeutics to Begin Phase 3 Trials for Non-Opioid Pain Therapy [Los Angeles Times (CA)]
Janus Henderson Group plc Ordinary Shares (JHG)
Last janus henderson group plc ordinary shares earnings: 4/30 04:00 am
Check Earnings Report
US:NYSE Investor Relations:
snl.com/irw/corporateprofile/4147331
Company Research
Source: Los Angeles Times
therapies for severe, underserved diseases, beginning with neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1). The round was co-led by RA Capital Management and Patient Square Capital's platform Enavate Sciences , joined by Abiogen Pharma, Janus Henderson Investors, Arkin Bio, Balyasny Asset Management, Transhuman Capital and Adage Capital Partners LP. The financing is expected to support a pivotal Phase 3 clinical trial of neridronate in CRPS-1, known as CRPS-RISE, and related regulatory preparations and pre-commercial activities. “We are launching Ambros with a seasoned leadership team and a therapy that has been used to treat CRPS in Italy for over ten years,” said Jay Hagan, chief executive officer of Ambros, in a statement. “With no approved medicines for CRPS-1 outside of Italy, we look forward to working with Abiogen Pharma to advance neridronate through Phase 3 and bring this therapy to patients who urgently need it.” CRPS-1 is a rare and debilitating conditi
Show less
Read more
Impact Snapshot
Event Time:
JHG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JHG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JHG alerts
High impacting Janus Henderson Group plc Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JHG
News
- Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease [Yahoo! Finance]Yahoo! Finance
- CNBC's UK Exchange newsletter: The battle for Britain's investment trusts [CNBC]CNBC
- Janus Henderson to Report Fourth Quarter and Full-Year 2025 Results [Yahoo! Finance]Yahoo! Finance
- Janus Henderson to Report Fourth Quarter and Full-Year 2025 ResultsBusiness Wire
- Andreessen Horowitz's shiny, new $15 billion reveals where the firm sees the biggest opportunities [Fortune]Fortune
JHG
Earnings
- 10/30/25 - Beat
JHG
Sec Filings
- 12/31/25 - Form 3
- 12/29/25 - Form DEFA14A
- 12/23/25 - Form SCHEDULE
- JHG's page on the SEC website